In vitro study of novel collagenase (Xiaflex®) on dupuytren's disease fibroblasts displays unique drug related properties

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Syed, Farhatullah ^a   Thomas, Alexis N ^a   Singh, Subir ^a   Kolluru, Venkatesh ^a   Hart, Susan G Emeigh ^d   Bayat, Ardeshir ^a,b,c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b WYTHENSHAWE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d Auxilium Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CLOSTRIDIOPEPTIDASE A; COLLAGEN; COMPLEMENTARY DNA; CYTOKINE; FIBRONECTIN; GELATINASE A; GELATINASE B; GROWTH FACTOR; LACTATE DEHYDROGENASE; NEW DRUG; TETRAZOLIUM; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL ADHESION; CELL ASSAY; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS; DOWN REGULATION; DRUG EXPOSURE; DRUG MECHANISM; DRUG TARGETING; DUPUYTREN CONTRACTURE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE STUDY; REAL TIME CELL ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; WESTERN BLOTTING; WOUND HEALING; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; NECROSIS; TIME; TREATMENT OUTCOME;

CLOSTRIDIUM HISTOLYTICUM;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DUPUYTREN CONTRACTURE; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION; HUMANS; MALE; MICROBIAL COLLAGENASE; MIDDLE AGED; NECROSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84863132958     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031430     Document Type: Article

References (82)

1. Bayat A, McGrouther DA, (2006) Management of Dupuytren's disease- Clear advice for an elusive condition. Annals of the Royal College of Surgeons of England 88: 3-8.
2. Thurston AJ, (2003) Dupuytren's disease. Journal of Bone and Joint Surgery- Series B 85: 469-477.
3. Caufield RJ, Edwards SG, (2008) Dupuytren disease: An update on recent literature. Current Orthopaedic Practice 19: 499-502.
4. Dupuytren G, (1834) Permanent retraction of the fingers, produced by an affection of the palmar fascia. Lancet 2: 222-225.
5. Shih B, Bayat A, (2010) Scientific understanding and clinical management of Dupuytren disease. Nat Rev Rheumatol 6: 715-726.
6. Hindocha S, John S, Stanley JK, Watson SJ, Bayat A, (2006) The heritability of Dupuytren's disease: Familial aggregation and its clinical significance. Journal of Hand Surgery 31: 204-210.
7. Bayat A, Watson JS, Stanley JK, Alansari A, Shah M, et al. (2002) Genetic susceptibility in Dupuytren's disease. Journal of Bone and Joint Surgery- Series B 84: 211-215.
8. An HS, Southworth SR, Jackson WT, Russ B, (1988) Cigarette smoking and Dupuytren's contracture of the hand. Journal of Hand Surgery 13: 872-874.
9. Gudmundsson KG, Arngrímsson R, Sigfússon N, Björnsson A, Jónsson T, (2000) Epidemiology of Dupuytren's disease: Clinical, serological, and social assessment. The Reykjavik Study. Journal of Clinical Epidemiology 53: 291-296.
10. Arkkila PET, Kantola IM, Viikari JSA, (1997) Dupuytren's disease: Association with chronic diabetic complications. Journal of Rheumatology 24: 153-159.
11. Attali P, Ink O, Pelletier G, Vernier C, Jean F, et al. (1987) Dupuytren's contracture, alcohol consumption, and chronic liver disease. Archives of Internal Medicine 147: 1065-1067.
12. Sanderson PL, Morris MA, Stanley JK, Fahmy NR, (1992) Lipids and Dupuytren's disease. Journal of Bone & Joint Surgery- British Volume 74: 923-927.
13. Hart MG, Hooper G, (2005) Clinical associations of Dupuytren's disease. Postgraduate Medical Journal 81: 425-428.
14. Livingstone JA, Field J, (1999) Algodystrophy and its association with Dupuytren's disease. Journal of Hand Surgery 24 B: 199-202.
15. Liss GM, Stock SR, (1996) Can Dupuytren's contracture be work-related?: review of the evidence. American Journal of Industrial Medicine 29: 521-532.
16. Degreef I, Steeno P, De Smet L, (2008) A survey of clinical manifestations and risk factors in women with Dupuytren's disease. Acta Orthopaedica Belgica 74: 456-460.
17. Murrell GAC, Hueston JT, (1990) Review article: Aetiology of Dupuytren's contracture. Australian and New Zealand Journal of Surgery 60: 247-252.
18. Tomasek JJ, Vaughan MB, Haaksma CJ, (1999) Cellular structure and biology of Dupuytren's disease. Hand Clinics 15: 21-34.
19. Brickley-Parsons D, Glimcher MJ, Smith RJ, (1981) Biochemical changes in the collagen of the palmar fascia in patients with Dupuytren's disease. Journal of Bone and Joint Surgery- Series A 63: 787-797.
20. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA, (2002) Myofibroblasts and mechano-regulation of connective tissue remodelling. Nature Reviews Molecular Cell Biology 3: 349-363.
21. Rayan GM, (2007) Dupuytren's disease: anatomy, pathology, presentation, and treatment. Instructional Course Lectures 56: 101-111.
22. Thomas A, Bayat A, (2010) The emerging role of Clostridium histolyticum collagenase in the treatment of Dupuytren disease. Ther Clin Risk Manag 6: 557-572.
23. Bayat A, (2010) Connective tissue diseases: A nonsurgical therapy for Dupuytren disease. Nat Rev Rheumatol 6: 7-8.
24. Desai SS, Hentz VR, (2010) Collagenase clostridium histolyticum for Dupuytren's contracture. Expert Opinion on Biological Therapy 10: 1395-1404.
25. Matsushita O, Koide T, Kobayashi R, Nagata K, Okabe A, (2001) Substrate Recognition by the Collagen-binding Domain of Clostridium histolyticum Class I Collagenase. Journal of Biological Chemistry 276: 8761-8770.
26. Steinbrink DR, Bond MD, Van Wart HE, (1985) Substrate specificity of beta-collagenase from Clostridium histolyticum. Journal of Biological Chemistry 260: 2771-2776.
27. Matsushita O, Jung CM, Katayama S, Minami J, Takahashi Y, et al. (1999) Gene duplication and multiplicity of collagenases in Clostridium histolyticum. Journal of Bacteriology 181: 923-933.
28. Mookhtiar KA, Van Wart HE, (1992) Clostridium histolyticum collagenases: a new look at some old enzymes. Matrix (Stuttgart, Germany) Supplement 1: 116-126.
29. Mallya SK, Mookhtiar KA, Van Wart HE, (1992) Kinetics of hydrolysis of type I, II, and III collagens by the class I and II Clostridium histolyticum collagenases. Journal of Protein Chemistry 11: 99-107.
30. French MF, Bhown A, Van Wart HE, (1992) Limited proteolysis of types I, II and III collagens at hyper-reactive sites by Clostridium histolyticum collagenase. Matrix (Stuttgart, Germany) Supplement 1: 134-135.
31. Watt AJ, Curtin CM, Hentz VR, (2010) Collagenase Injection as Nonsurgical Treatment of Dupuytren's Disease: 8-Year Follow-Up. Journal of Hand Surgery 35: 534-539.
32. Hurst LC, Badalamente MA, Hentz VR, Hotchkiss RN, Kaplan FTD, et al. (2009) Injectable collagenase clostridium histolyticum for Dupuytren's contracture. New England Journal of Medicine 361: 968-979.
33. Starkweather KD, Lattuga S, Hurst LC, Badalamente MA, Guilak F, et al. (1996) Collagenase in the treatment of Dupuytren's disease: An in vitro study. The Journal of Hand Surgery 21: 490-495.
34. Badalamente MA, Hurst LC, (2000) Enzyme injection as nonsurgical treatment of Dupuytren's disease. The Journal of Hand Surgery 25: 629-636.
35. Badalamente MA, Hurst LC, Hentz VR, (2002) Collagen as a clinical target: Nonoperative treatment of Dupuytren's disease. Journal of Hand Surgery 27: 788-798.
36. Pharmaceuticals A, (2009) Briefing Document for Collagenase Clostridium Histolyticum (AA4500) in the Treatment of Advanced Dupuytren's Disease (for United States FDA Arthritis Advisory Committee Meeting). In: Committee AA, editors. Washington DC.
37. Van der Rest M, Garrone R, (1991) Collagen family of proteins. FASEB J 5: 2814-2823.
38. Prockop DJ, Kivirikko KI, (1995) Collagens: molecular biology, diseases, and potentials for therapy. Annu Rev Biochem 64: 403-434.
39. Gelse K, Poschl E, Aigner T, (2003) Collagens-structure, function, and biosynthesis. Adv Drug Deliv Rev 55: 1531-1546.
40. Ricard-Blum S, Ruggiero F, (2005) The collagen superfamily: from the extracellular matrix to the cell membrane. Pathol Biol (Paris) 53: 430-442.
41. Bazin S, Leloius M, Duance VC, Sims TJ, Bailey AJ, Gabbiani G, D'Andiran G, Pizzolato G, Browski A, Nicoletis C, Delaunay A, (1980) Biochemistry and histology of the connective tissue of Dupuytren's disease lesions. European Journal of Clinical Investigation 10: 9-16.
42. Murrell GA, Francis MJ, Howlett CR, (1989) Dupuytren's contracture. Fine structure in relation to aetiology. Journal of Bone & Joint Surgery- British Volume 71: 367-373.
43. Murrell GA, Francis MJ, Bromley L, (1987) Free radicals and Dupuytren's contracture. British Medical Journal Clinical Research Ed 295: 1373-1375.
44. Del Carlo M, Cole AA, Hart SGE, Levine LA, (2009) Comparative analysis of collagen degradation in Peyronie's Disease plaque and Dupuytren's contracture cord tissues injected with mixed collagenase subtypes. The Journal of urology 181: 279-279.
45. Hindocha S, Iqbal SA, Farhatullah S, Paus R, Bayat A, (2010) Characterization of stem cells in Dupuytren's disease. Br J Surg 98: 308-315.
46. Duong HS, Zhang Q, Kobi A, Le A, Messadi DV, (2005) Assessment of Morphological and Immunohistological Alterations in Long-Term Keloid Skin Explants. Cells Tissues Organs 181: 89-102.
47. Lu Z, Hasse S, Bodo E, Rose C, Funk W, et al. (2007) Towards the development of a simplified long-term organ culture method for human scalp skin and its appendages under serum-free conditions. Experimental dermatology 16: 37-44.
48. Xing JZ, Zhu L, Jackson JA, Gabos S, Sun XJ, et al. (2005) Dynamic monitoring of cytotoxicity on microelectronic sensors. Chem Res Toxicol 18: 154-161.
49. Atienza JM, Zhu J, Wang X, Xu X, Abassi Y, (2005) Dynamic monitoring of cell adhesion and spreading on microelectronic sensor arrays. Journal of biomolecular screening 10: 795-805.
50. Syed F, Ahmadi E, Iqbal SA, Singh S, McGrouther DA, et al. (2010) Fibroblasts from the growing margin of keloid scars produce higher levels of collagen I and III expression compared to intra- and extra-lesional sites: clinical implications for lesional site-directed therapy. Br J Dermatol 164: 83-96.
51. Sebastian A, Syed F, McGrouther DA, Colthurst J, Paus R, et al. (2010) A novel in vitro assay for electrophysiological research on human skin fibroblasts: Degenerate electrical waves downregulate collagen I expression in keloid fibroblasts. Experimental dermatology 20: 64-68.
52. Olive DM, (2004) Quantitative methods for the analysis of protein phosphorylation in drug development. Expert review of proteomics 1: 327-341.
53. Chen H, Kovar J, Sissons S, Cox K, Matter W, et al. (2005) A cell-based immunocytochemical assay for monitoring kinase signaling pathways and drug efficacy. Analytical biochemistry 338: 136-142.
54. Hannoush RN, (2008) Kinetics of Wnt-driven b-catenin stabilization revealed by quantitative and temporal imaging. PloS one 3: e3498.
55. Bateman JF, Mascara T, Chan D, Cole WG, (1984) Abnormal type I collagen metabolism by cultured fibroblasts in lethal perinatal osteogenesis imperfecta. Biochem J 217: 103-115.
56. GaM GabbianiD, (1985) The myofibroblasts in Dupuytren's disease and other fibromatoses. In: HJTaT R, editors. Dupuytren's Disease. 2nd ed Edinburgh Churchill Livingstone pp. 86-93.
57. Murrell GA, Francis MJ, Bromley L, (1991) The collagen changes of Dupuytren's contracture. J Hand Surg Br 16: 263-266.
58. Rehman S, Salway F, Stanley JK, Ollier WE, Day P, et al. (2008) Molecular phenotypic descriptors of Dupuytren's disease defined using informatics analysis of the transcriptome. J Hand Surg Am 33: 359-372.
59. Howard JC, Varallo VM, Ross DC, Faber KJ, Roth JH, et al. (2004) Wound healing-associated proteins Hsp47 and fibronectin are elevated in Dupuytren's contracture. J Surg Res 117: 232-238.
60. Dave SA, Banducci DR, Graham WP 3rd, Allison GM, Ehrlich HP, (2001) Differences in alpha smooth muscle actin expression between fibroblasts derived from Dupuytren's nodules or cords. Exp Mol Pathol 71: 147-155.
61. Hindman HB, Marty-Roix R, Tang JB, Jupiter JB, Simmons BP, et al. (2003) Regulation of expression of alpha-smooth muscle actin in cells of Dupuytren's contracture. Journal of Bone & Joint Surgery- British Volume 85: 448-455.
62. Verjee LS, Midwood K, Davidson D, Essex D, Sandison A, et al. (2009) Myofibroblast distribution in Dupuytren's cords: correlation with digital contracture. J Hand Surg Am 34: 1785-1794.
63. Verjee LS, Midwood K, Davidson D, Eastwood M, Nanchahal J, (2010) Post-transcriptional regulation of alpha-smooth muscle actin determines the contractile phenotype of Dupuytren's nodular cells. J Cell Physiol 224: 681-690.
64. Shih B, Wijeratne D, Armstrong DJ, Lindau T, Day P, et al. (2009) Identification of Biomarkers in Dupuytren's Disease by Comparative Analysis of Fibroblasts Versus Tissue Biopsies in Disease-Specific Phenotypes. The Journal of Hand Surgery 34: 124-136.
65. Zhang AY, Fong KD, Pham H, Nacamuli RP, Longaker MT, et al. (2008) Gene expression analysis of Dupuytren's disease: the role of TGF-beta2. J Hand Surg Eur Vol 33: 783-790.
66. Baird KS, Crossan JF, Ralston SH, (1993) Abnormal growth factor and cytokine expression in Dupuytren's contracture. J Clin Pathol 46: 425-428.
67. Badalamente MA, Hurst LC, Grandia SK, Sampson SP, (1992) Platelet-derived growth factor in Dupuytren's disease. J Hand Surg Am 17: 317-323.
68. Igarashi A, Nashiro K, Kikuchi K, Sato S, Ihn H, et al. (1996) Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. Journal of Investigative Dermatology 106: 729-733.
69. Bisson MA, McGrouther DA, Mudera V, Grobbelaar AO, (2003) The different characteristics of Dupuytren's disease fibroblasts derived from either nodule or cord: Expression of a-smooth muscle actin and the response to stimulation by TGF-b1. Journal of Hand Surgery 28 B: 351-356.
70. Murrell G, Francis M, Bromley L, (1990) Modulation of fibroblast proliferation by oxygen free radicals. Biochem J 265: 659-665.
71. Baird KS, Crossan JF, Ralston SH, (1993) Abnormal growth factor and cytokine expression in Dupuytren's contracture. Journal of Clinical Pathology 46: 425-428.
72. Terek RM, Jiranek WA, Goldberg MJ, Wolfe HJ, Alman BA, (1995) The expression of platelet-derived growth-factor gene in Dupuytren contracture. J Bone Joint Surg Am 77: 1-9.
73. Pilcher BK, Dumin JA, Sudbeck BD, Krane SM, Welgus HG, et al. (1997) The activity of collagenase-1 is required for keratinocyte migration on a type I collagen matrix. J Cell Biol 137: 1445-1457.
74. Riley KN, Herman IM, (2005) Collagenase promotes the cellular responses to injury and wound healing in vivo. J Burns Wounds 4: e8.
75. Shi L, Ermis R, Garcia A, Telgenhoff D, Aust D, (2010) Degradation of human collagen isoforms by Clostridium collagenase and the effects of degradation products on cell migration. Int Wound J 7: 87-95.
76. Badalamente MA, Hurst LC, (2007) Efficacy and Safety of Injectable Mixed Collagenase Subtypes in the Treatment of Dupuytren's Contracture. Journal of Hand Surgery 32: 767-774.
77. Hurst LC, Badalamente M, Smith T, (2009) The authors reply. New England Journal of Medicine 361: 2579-2580.
78. Jung C MO, Katayama S, et al. (1999) Identification of metal ligands in the Clostridia histolyticum ColH Collagenase. J Bacteriology 181: 2816-2822.
79. Kim HA, Suh DI, Song YW, (2001) Relationship between chondrocyte apoptosis and matrix depletion in human articular cartilage. J Rheumatol 28: 2038-2045.
80. Atkinson RK, Wright LG, (1992) The involvement of collagenase in the necrosis induced by the bites of some spiders. Comp Biochem Physiol C 102: 125-128.
81. Herrmann H, Dessau W, Fessler LI, Von Der Mark K, (1980) Synthesis of Types I, III and AB, Collagen by Chick Tendon Fibroblasts in vitro. European Journal of Biochemistry 105: 63-74.
82. Al-Qattan MM, (2006) Factors in the pathogenesis of Dupuytren's contracture. Journal of Hand Surgery- American Volume 31: 1527-1534.